Clinical Effect of High-dose Ambroxol Combined with Moxifloxacin on Elderly Patients with Chronic Obstructive Pulmonary Disease and Severe Pneumonia  

作　　者：MIYESEERKadeer ABULMITIAbulizi 

机构地区：[1] Kashgar Pulmonary Hospital, Kashgar Xinjiang 844000, China [2] Jiashi People's Hospital, Jiashi Xinjiang 844300, China

出　　处：《外文科技期刊数据库(文摘版)医药卫生》2022年第5期083-086,共4页

摘　　要：Objective: to analyze the clinical treatment of elderly patients with chronic obstructive pulmonary disease and severe pneumonia, and to explore the therapeutic effect of high-dose ambroxol combined with moxifloxacin. Methods: a total of 80 samples of elderly patients with chronic obstructive pulmonary disease and severe pneumonia were selected and admitted from March 2021 to March 2022. The patients were divided into experimental group and control group with a sample size of 40 in each group. The two groups of therapeutic drugs are ambroxol and moxifloxacin, the difference lies in the dosage of ambroxol, the experimental group is a large dose, and the control group is a conventional dose. The pulmonary function, inflammatory reaction and quality of life of the two groups before and after treatment were compared. Results: after one weeks treatment, there were significant differences in pulmonary function and inflammatory indexes such as forced expiratory volume (FEV1), forced vital capacity (FVC), C-reactive protein (CRP) and procalcitonin (PCT) levels between the two groups in the first second. The values of the first two indexes in the test group were higher, while those of the second two indexes were lower. The data of the test group and the control group showed P < 0.05 through statistical software analysis. The professional scale was used to evaluate the quality of life of the patients, and it was found that there were significant differences between the two groups in terms of each index data. The scores of the experimental group were all better, and the results of the statistical software analysis of the data of the control group were all P < 0.05. Conclusion: in the treatment of elderly patients with chronic obstructive pulmonary disease and severe pneumonia, the use of high-dose ambroxol combined with moxifloxacin can better improve the patients lung function, reduce the inflammatory response, and thus effectively improve the quality of life of patients.

关 键 词：AMBROXOL MOXIFLOXACIN senile chronic obstructive pulmonary disease severe pneumonia 

分 类 号：R[医药卫生]